{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:48:19Z","timestamp":1793998099474,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41409-023-01960-2","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:06:41Z","timestamp":1680260801000},"page":"701-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy"],"prefix":"10.1038","volume":"58","author":[{"given":"Shan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3471-4338","authenticated-orcid":false,"given":"Cheng","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"1960_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J, Fu W-J, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15:86.","journal-title":"J Hematol Oncol"},{"key":"1960_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"1960_CR3","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an Anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. JCO. 2022;41:1265\u201374.","DOI":"10.1200\/JCO.22.00842"},{"key":"1960_CR4","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156\u2013165.","journal-title":"Hepatology"},{"key":"1960_CR5","doi-asserted-by":"publisher","first-page":"e1372","DOI":"10.1093\/cid\/ciab302","volume":"73","author":"SK Lee","year":"2021","unstructured":"Lee SK, Sung PS, Park S-S, Min C-K, Nam H, Jang JW, et al. Reactivation of resolved hepatitis B after daratumumab for multiple myeloma. Clin Infect Dis. 2021;73:e1372\u2013e1375.","journal-title":"Clin Infect Dis"},{"key":"1960_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","volume":"20","author":"S Yoo","year":"2022","unstructured":"Yoo S, Lee D, Shim JH, Kim KM, Lim Y-S, Lee HC, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment. Clin Gastroenterol Hepatol. 2022;20:898\u2013907.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1960_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00228-018-2487-4","volume":"74","author":"Y-C Su","year":"2018","unstructured":"Su Y-C, Lin P-C, Yu H-C, Wu C-C. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. Eur J Clin Pharm. 2018;74:1111\u20139.","journal-title":"Eur J Clin Pharm"},{"key":"1960_CR8","doi-asserted-by":"publisher","first-page":"e001072","DOI":"10.1136\/jitc-2020-001072","volume":"8","author":"P-C Lee","year":"2020","unstructured":"Lee P-C, Chao Y, Chen M-H, Lan K-H, Lee I-C, Hou M-C, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2020;8:e001072.","journal-title":"J Immunother Cancer"},{"key":"1960_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0790-y","volume":"7","author":"J Wei","year":"2019","unstructured":"Wei J, Zhu X, Mao X, Huang L, Meng F, Zhou J. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer. 2019;7:315.","journal-title":"J Immunother Cancer"},{"key":"1960_CR10","doi-asserted-by":"publisher","first-page":"638678","DOI":"10.3389\/fimmu.2021.638678","volume":"12","author":"P Li","year":"2021","unstructured":"Li P, Zhou L, Ye S, Zhang W, Wang J, Tang X, et al. Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis. Front Immunol. 2021;12:638678.","journal-title":"Front Immunol"},{"key":"1960_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","volume":"34","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu Y, Tan X, Pan B, Jian Ge, Qi K, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia. 2020;34:2704\u20137.","journal-title":"Leukemia"},{"key":"1960_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.16951","volume":"191","author":"W Liu","year":"2020","unstructured":"Liu W, Huang W, Wang M, Lv R, Li J, Wang Y, et al. Risk of hepatitis B reactivation is controllable in patients with B\u2010cell lymphoma receiving anti\u2010CD19 CAR T cell therapy. Br J Haematol. 2020;191:126\u20139.","journal-title":"Br J Haematol"},{"key":"1960_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2020004907","volume":"136","author":"W Cao","year":"2020","unstructured":"Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood. 2020;136:516\u20139.","journal-title":"Blood"},{"key":"1960_CR14","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res. 2021;27:6384\u201392.","journal-title":"Clin Cancer Res"},{"key":"1960_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1960_CR16","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1960_CR17","doi-asserted-by":"publisher","first-page":"e000927","DOI":"10.1136\/jitc-2020-000927","volume":"8","author":"L Han","year":"2020","unstructured":"Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang B, et al. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer. 2020;8:e000927.","journal-title":"J Immunother Cancer"},{"key":"1960_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0002-2","volume":"7","author":"Y Tsukune","year":"2017","unstructured":"Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, et al. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan. Blood Cancer J. 2017;7:631.","journal-title":"Blood Cancer J"},{"key":"1960_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299\u2013307.","journal-title":"J Med Virol"},{"key":"1960_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297\u2013309.","journal-title":"Gastroenterology"},{"key":"1960_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B\u2010cell lymphoma. Br J Haematol. 2021;195:388\u201398.","journal-title":"Br J Haematol"},{"key":"1960_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B\u2010cell lymphoma. Br J Haematol. 2021;194:690\u2013700.","journal-title":"Br J Haematol"},{"key":"1960_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221\u2013.e3.","journal-title":"Gastroenterology"},{"key":"1960_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","volume":"19","author":"B Rehermann","year":"2013","unstructured":"Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19:859\u201368.","journal-title":"Nat Med"},{"key":"1960_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719\u201329.","journal-title":"Clin Infect Dis"},{"key":"1960_CR26","doi-asserted-by":"publisher","first-page":"30642","DOI":"10.18632\/oncotarget.8907","volume":"7","author":"M-Y Zhang","year":"2016","unstructured":"Zhang M-Y, Zhu G-Q, Shi K-Q, Zheng J-N, Cheng Z, Zou Z-L, et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642\u201358.","journal-title":"Oncotarget"},{"key":"1960_CR27","doi-asserted-by":"publisher","first-page":"e0131545","DOI":"10.1371\/journal.pone.0131545","volume":"10","author":"W-C Chen","year":"2015","unstructured":"Chen W-C, Cheng J-S, Chiang P-H, Tsay F-W, Chan H-H, Chang H-W, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PLoS ONE. 2015;10:e0131545.","journal-title":"PLoS ONE"},{"key":"1960_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2016.0024","volume":"22","author":"V Pattullo","year":"2016","unstructured":"Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219\u201337.","journal-title":"Clin Mol Hepatol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01960-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01960-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01960-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:03:37Z","timestamp":1686128617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-01960-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-01960-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author YZ and AHCis employed by Shanghai YaKe Biotechnology Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}